CAW
ONC

Cornerstone Advisors (Washington)’s BeOne Medicines Ltd ONC Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-250
Closed -$31K – 1403
2019
Q2 		$31K Buy
250
+26
+12% +$3.3K ﹤0.01% 541
2019
Q1 		$30K Buy
224
+11
+5% +$1.48K ﹤0.01% 509
2018
Q4 		$30K Buy
+213
New +$28.2K 0.01% 416

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Cornerstone Advisors (Washington)'s ONC Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of BeOne Medicines Ltd (ONC) in Q3 2019, closing a stake of 250 shares — an estimated $31K sold.

Cornerstone Advisors (Washington) first reported a position in ONC in Q4 2018 and held it in 3 quarters. The position peaked at $31K in Q2 2019. 196 funds tracked by Wall St. Rank hold ONC as of Q3 2019.

  • Cornerstone Advisors (Washington) reported no remaining BeOne Medicines Ltd position as of Q3 2019 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 250 BeOne Medicines Ltd shares in Q3 2019, an estimated $31K.
  • Cornerstone Advisors (Washington) first reported a position in BeOne Medicines Ltd in Q4 2018 and held it in 3 quarters.
  • Cornerstone Advisors (Washington)'s BeOne Medicines Ltd position peaked at $31K in Q2 2019.
  • 196 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.